Oct 2026· Diabetes, obesity and metabolism· 0 citations· 49 references
Medicine
TL;DR
In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.
Abstract
INTRODUCTION
Given the significant burden that diabetes self-management poses, it is important to assess patient-reported outcomes (PROs) for Type 2 diabetes (T2D) treatments in clinical trials and real-world studies. Complex insulin regimens are associated with increased risk of hypoglycaemia and body weight gain, which could negatively impact treatment adherence and, therefore, achievement of glycaemic targets. iGlarLixi is a once-daily fixed-ratio combination of insulin glargine 100 U/mL and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide. iGlarLixi is an effective treatment alternative to complex insulin regimens, with a favourable between-group difference in body weight and reduced risk of hypoglycaemia.
Methods
This is the first review to summarise data from multiple validated PRO measures for recent iGlarLixi studies (Soli-CGM, SoliMix, Soli-SWITCH, IDEAL, SUCCESS and SIMPLIFY JP), including: Global Treatment Effectiveness Evaluation, Audit of Diabetes Dependent Quality of Life, Diabetes Medication Satisfaction Tool, Diabetes Therapy-Related Quality of Life, Diabetes Treatment Satisfaction Questionnaire, Hypoglycaemic Attitudes and Behaviour Scale and Treatment-Related Impact Measure Diabetes.
Results
In clinical studies, once-daily iGlarLixi was associated with numerical improvements in selected treatment satisfaction measures in those who switched from: complex insulin regimens (once- or twice-daily premixed insulin and basal-bolus insulin), basal insulin or oral glucose-lowering medications. Additionally, in real-world studies, iGlarLixi was generally associated with improvements in treatment satisfaction and quality of life outcomes in adults with T2D who previously received basal-bolus insulin or oral glucose-lowering medications ± basal insulin or GLP-1 RAs.
Conclusions
In conclusion, a once-daily injection of iGlarLixi may offer a clinically beneficial, simplified treatment option for adults with T2D compared with complex insulin-based regimens.
Background: Type 2 diabetes mellitus (T2DM) is a progressive disorder with high cardiovascular (CV) risk, often inadequately controlled on monotherapy. This study aimed to evaluate real-world efficacy, safety, CV outcomes, tolerability and adherence of the empagliflozin, sitagliptin and metformin fixed-dose combination...
Nandkishor Shingne, Masiha Asar, Abdul Lateef Shaikh et al.· World Journal of Advanced Re...· 0 citations
In adults with type 2 diabetes mellitus, insulin-containing regimens during Ramadan were associated with a modest reduction in HbA 1c ; however, the clinical significance of this reduction remains uncertain.
H. Gad, T. Hayat, Z. Dabbous et al.· BMC Endocrine Disorders· 0 citations
INTRODUCTION
The global burden of type 2 diabetes mellitus (T2DM) is rapidly increasing, with India contributing significantly to the disease prevalence and associated economic burden. Despite metformin being the first-line therapy, many patients require combination treatment due to the progressive and multifactorial n...
Prakash Kurmi, M. Singh, Vishal Gupta et al.· Advances in Therapy· 0 citations
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in obesity and type 2 diabetes mellitus (T2DM), but comparative real-world evidence from the Middle East remains limited. We compared the effectiveness, documented adverse events, adherence and persistence of once-weekly semaglutide and o...
Najwa Al Himali, Hanan Al Habsi, Ahmed Al Mushrafi et al.· Journal of Clinical Medicine· 0 citations
Background: Type 2 diabetes mellitus (T2DM) is a chronic global health burden associated with cardiovascular (CV) and renal complications. This study aimed to evaluate real-world efficacy, cardiometabolic outcomes, and long-term outcomes of the empagliflozin + linagliptin add-on therapy to metformin in T2DM patients.
M...
Nandkishor Shingne, Vrunda Patel, Swati Tiwari et al.· World Journal of Advanced Re...· 0 citations
INTRODUCTION
The aim of this study was to compare patient-reported outcomes (PROs) related to hypoglycemia recovery with FLO23011, a novel multi-energy substrate for hypoglycemia (MESH) recovery drink combining 15 g glucose with beta-hydroxybutyrate (BHB), versus standard glucose gel in adults with type 1 diabetes, and...
D. Russell-Jones, E. Meehan, V. Smout et al.· Diabetes Therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.